May 9, 2026
Better access to popular GLP-1 drugs is coming this summer for the millions of adults on Medicare that may be struggling with weight loss.
Thanks to a GLP-1 Bridge pilot program announced by President Trump (1) and the Centers for Medicare & Medicaid Services (CMS) (2) this month, adults with Medicare Plan D coverage can access the weight loss drugs for a $50 copay.
Advertisement
The move is a noticeable shift for Medicare, which has historically denied coverage for GLP-1 medications for weight loss purposes. More than 66 million people in the U.S. get their health coverage from Medicare. Seniors and other qualifying Medicare recipients have largely been limited to GLP-1 drugs to treat health conditions like diabetes or cardiovascular disease. (3)
The 18-month program will run from July 1 until the end of next year, and will enable CMS to collect more data on the utilization of weight-loss drugs to share with Medicare plan providers. The goal is to roll out a permanent marketplace offering in 2028, BALANCE. (4)
How GLP-1 Medicare Bridge works
In order to access weight loss medications through GLP-1 Bridge, you must be enrolled in a Medicare Part D plan, which covers prescription drugs. Though, you will still need prior authorization from your doctor in order to receive treatment.
The good news is your doctor doesn't need to be listed as a Medicare provider to write a prescription or submit prior authorization to Humana, the plan administrator, on your behalf.
Eligibility will largely be determined by your body mass index. (5) If it's 27 or higher, you'll likely qualify. This is also true if you have a condition such as heart disease or prediabetes. Once you're approved, you'll pay $50 at the pharmacy.
At launch, the program will offer both the pill and injectible forms of Wegovy, Zepbound's KwikPen and the Foundayo pill.
Must Read
- Dave Ramsey warns nearly 50% of Americans are making 1 big Social Security mistake — are you doing the same?
- Thanks to Jeff Bezos, you can now become a landlord for as little as $100 — and no, you don't have to deal with tenants or fix freezers. Here's how
- Robert Kiyosaki says this 1 asset will surge 400% in a year and begs investors not to miss this ‘explosion’
Join 250,000+ readers and get Moneywise’s best stories and exclusive interviews first — clear insights curated and delivered weekly. Subscribe now.
Bridging the financial gap
A November 2025 KFF survey found that one in eight adults take GLP-1 drugs such as Wegovy or Ozempic for weight loss or to treat a health condition like diabetes. In the same study, however, respondents said the costs for the drugs were too high. (6)
In fact, weight loss medications can cost more than $1,000 without insurance. (7) Even with coupons or patient assistance programs, they can still cost between $149 to $299 for initial doses. (8)
A $50 copay at your local pharmacy through the GLP-1 Bridge program is substantially better than that. And yet, some working class families may not be able to afford the monthly expense in a world with sticky inflation and rising gas and food prices.
Advertisement
Americans with private insurance, by comparison, can score GLP-1 drugs for $25 or less. (9) The caveat here is that coverage can widely vary by insurance provider. If you're on medicaid, GLP-1 coverage options are decided by your state. As of January 2026, only 13 U.S. states cover GLP-1 drugs for weight-loss management through Medicaid.
Downsides of the Medicare GLP-1 Bridge Program
As with any government program, there are a few notable drawbacks to the GLP-1 Bridge program.
For one, the pilot has an expiration date of December 31, 2027. While CMS is hopeful it will roll out a permanent BALANCE offering in 2028, its launch isn't guaranteed.
If a permanent solution isn't launched or the GLP-1 Bridge program isn't extended, users will be at risk of regaining weight they lost due to their appetite and "food noise" returning. (10) With it, the risk of health conditions like diabetes become more difficult to control, studies have shown. (11)
Medicare Plan D users already taking a weight loss medication in pill or injectable form for a pre-existing qualifying condition like Type-2 diabetes or sleep apnea will need to continue receiving the drugs through their plan. This may end up being higher than the $50 copay.
Finally, newcomers to GLP-1 drugs through the bridge program will not be able to have monthly $50 costs counted towards their out-of-pocket expenses.
Article Sources
We rely only on vetted sources and credible third-party reporting. For details, see our ethics and guidelines.
Reuters (1); Centers for Medicare & Medicaid Services (2),(4); KFF (3),(6); NPR (5); GoodRx (7),(8); USA Today (9); Harvard Health (10); AARP (11)
You May Also Like
- Turning 50 with $0 saved for retirement? Most people don’t realize they’re actually just entering their prime earning decade. Here are 6 ways to catch up fast
- Inside a $1B real estate fund offering access to thousands of income-producing rental properties — with flexible minimums starting at $10
- Vanguard’s outlook on U.S. stocks is raising alarm bells for retirees. Here’s why and how to protect yourself
- Here are 5 easy ways to own multiple properties like Bezos and Beyoncé. You can start with $10 (and no, you don’t have to manage a single thing)
Danni Santana is a journalist based out of New York City with a decade of experience reporting and editing business stories about retail, restaurants, sports, and personal finance.
